Oxadiazole-Containing Macrocyclic Peptides Potentiate Azole Activity against Pathogenic Candida Species
Author(s) -
Nicole M. Revie,
Nicole Robbins,
Luke Whitesell,
John R. Frost,
Solomon D. Appavoo,
Andrei K. Yudin,
Leah E. Cowen
Publication year - 2020
Publication title -
msphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.749
H-Index - 39
ISSN - 2379-5042
DOI - 10.1128/msphere.00256-20
Subject(s) - azole , fluconazole , candida albicans , efflux , fungal pathogen , microbiology and biotechnology , antimicrobial , biology , chemistry , antifungal , pathogen , biochemistry
Fungal infections, such as those caused by pathogenic Candida species, pose a serious threat to human health. Treating these infections relies heavily on the use of azole antifungals; however, resistance to these drugs develops readily, demanding novel therapeutic strategies. This study characterized the antifungal activity of a series of molecules that possess unique chemical attributes and the ability to traverse cellular membranes. We observed that many of the compounds increased the activity of the azole fluconazole against Candida albicans , without blocking the action of drug efflux pumps. These molecules also increased the efficacy of azoles against other Candida species, including the emerging azole-resistant pathogen Candida auris . Thus, we describe a novel chemical scaffold with broad-spectrum bioactivity against clinically important fungal pathogens.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom